Cepheid (NASDAQ:CPHD) Increases Lower End Guidance

Filed in Cepheid, GARP Research, Gold Bullion prices, Guidance, o, revenue, shares by on December 7, 2010 0 Comments

During their most recent quarterly report, Cepheid (NASDAQ:CPHD) said they’re increasing the lower end of their full year guidance going forward. . GARP Research commented, “Shares of Cepheid jumped after it reported 2Q10 results. Total revenue grew 21% y/y to $49.6 million, driven by a 41% jump in the clinical segment. This was offset by an expected 35% y/y decline for the Biothreat business,

Continue Reading »